Related Experiment Video
Updated: Apr 4, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
3.6K
Mycophenolate mofetil for lupus nephritis: an update
1a Department of Medicine, Tuen Mun Hospital, Hong Kong, China.
Expert Review of Clinical Immunology
|September 15, 2015
Summary
Mycophenolate mofetil (MMF) is a leading treatment for lupus nephritis, offering a safer profile than cyclophosphamide. Combining MMF with tacrolimus shows promise for inducing remission in Chinese patients.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) frequently causes severe kidney disease (lupus nephritis), leading to significant morbidity and mortality.
- Effective immunosuppression is crucial for managing kidney inflammation and preventing long-term renal failure.
Purpose of the Study:
- To review the current treatment landscape for lupus nephritis.
- To evaluate the efficacy and safety of mycophenolate mofetil (MMF) and other therapeutic strategies.
Main Methods:
- Review of controlled trials and recent studies on lupus nephritis treatment.
- Comparison of MMF with cyclophosphamide and azathioprine.
- Assessment of novel biologic agents and combination therapies.
Main Results:
- MMF is a first-line treatment for lupus nephritis, demonstrating comparable efficacy to cyclophosphamide for induction and superior efficacy for maintenance therapy.
- Combining MMF with biologics has not consistently improved outcomes in refractory cases.
- A low-dose MMF and tacrolimus combination showed higher efficacy than intravenous pulse cyclophosphamide in inducing remission in Chinese patients.
Conclusions:
- MMF is a well-established and effective treatment for lupus nephritis.
- Emerging combination therapies, such as MMF with tacrolimus, warrant further investigation.
- Therapeutic drug monitoring of mycophenolic acid levels may optimize MMF efficacy.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
684
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
684
01:24Nephrotic Syndrome I : Introduction
989
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
989
01:26Nephrotic Syndrome II : Assessment and Medical Management
325
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
325
01:24Nephrotic Syndrome III : Nursing Management
448
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
448
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
65
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
65
01:11Renal Failure: Dose Adjustments
583
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
583